KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Cash from Financing Activities data on record, last reported at -$4.6 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 412.08% year-over-year to -$4.6 million; the TTM value through Dec 2025 reached $601000.0, up 105.16%, while the annual FY2025 figure was $601000.0, 105.16% up from the prior year.
  • Cash from Financing Activities reached -$4.6 million in Q4 2025 per RIGL's latest filing, down from $4.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $59.2 million in Q2 2021 and bottomed at -$9.8 million in Q3 2024.
  • Average Cash from Financing Activities over 5 years is $3.8 million, with a median of $451000.0 recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: surged 1911.31% in 2022, then tumbled 1032.57% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.1 million in 2021, then tumbled by 293.18% to -$2.1 million in 2022, then soared by 123.19% to $486000.0 in 2023, then surged by 201.44% to $1.5 million in 2024, then plummeted by 412.08% to -$4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$4.6 million in Q4 2025, $4.3 million in Q3 2025, and $418000.0 in Q2 2025.